Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Depression

Ketamine repairs reward circuitry to reverse stress-induced anhedonia

by Eric W. Dolan
July 9, 2025
in Depression, Ketamine
[Adobe Stock]

[Adobe Stock]

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

A single low dose of the anesthetic ketamine restored the ability to enjoy sweet treats and social contact in mice that had been made apathetic by long-term stress, according to new research published in Neuron. The same injection also repaired weakened connections onto a specific group of reward-related brain cells. When those repaired connections were blocked, the animals’ recovery disappeared—suggesting the synaptic fix is a key part of ketamine’s sustained antidepressant effects.

Originally developed as an anesthetic in the 1960s, ketamine has more recently drawn attention for its fast-acting antidepressant properties. Over the past two decades, clinicians have found that sub-anesthetic doses can lift mood within hours in many people with major depression who do not respond to conventional medications. That rapid action stands in contrast to commonly prescribed drugs like selective serotonin reuptake inhibitors, which often take weeks to alleviate symptoms.

One symptom of depression that appears to respond especially well to ketamine is anhedonia—the loss of pleasure in normally rewarding experiences. Yet it remains unclear which brain circuits are responsible for the drug’s lasting effects on mood and motivation. The new study set out to identify those changes down to the level of individual synapses.

“Depression is a leading cause of morbidity and mortality worldwide, and it is projected to become the second leading cause of disability by 2030,” said study author Marco Pignatelli, an assistant professor of psychiatry at Washington University School of Medicine in St. Louis.

“Despite the urgent need to address depression as a public health priority, current pharmacotherapies require prolonged administration—weeks, if not months—for clinical improvement, and are often associated with high non-response rates. In contrast, a single sub-anesthetic dose of ketamine induces a rapid antidepressant effect in about 70% of treatment-resistant patients.”

“Importantly, this improvement often occurs within the context of anhedonia,” he added. “Conventional antidepressants do poorly in relieving anhedonia, which is one of the two core symptoms used to diagnose major depression. That makes ketamine a promising and unique pharmacological option. However, without understanding the circuits and synapses that support this effect, our ability to design safer, more targeted medications is limited.”

To model anhedonia in mice, the researchers implanted slow-release corticosterone pellets under the animals’ skin to mimic chronic stress. Over three weeks, the hormone reduced the animals’ interest in sweetened water, decreased time spent with other mice, and lowered their willingness to work for rewards in a progressive ratio task where nose-pokes earned sugar pellets.

Twenty-four hours before each test, half the stressed mice received a single injection of ketamine at 10 milligrams per kilogram—a dose well below what’s used for anesthesia. The rest received saline, as did a group of unstressed control mice. Ketamine restored reward-seeking behavior across all tasks, while saline had no effect. The drug did not increase overall activity levels, ruling out general stimulation as an explanation.

To uncover what had changed in the brain, the researchers prepared thin slices from another group of similarly treated mice and recorded electrical activity in the nucleus accumbens, a key hub for processing reward. They focused on medium spiny neurons that express dopamine receptor type 1, a subtype linked to motivation and approach behavior.

Chronic stress reduced the strength and frequency of excitatory inputs to these neurons, but ketamine reversed this effect within a day—possibly as soon as one hour after injection. These changes were not observed in neighboring neurons that express dopamine receptor type 2, highlighting the cell-type specificity of the effect.

To test whether these restored synapses were necessary for ketamine’s behavioral benefits, the researchers used a molecular technique to block them. They introduced a HaloTag protein into dopamine receptor type 1 neurons, allowing them to tether a glutamate receptor blocker to just those cells. Delivering the blocker into the nucleus accumbens 24 hours after ketamine erased the previously observed improvements in sugar preference, sociability, and motivation. Blocking the same receptors on dopamine receptor type 2 neurons had no effect, pinpointing the importance of the type 1 cells.

The team then asked whether strengthening the same synapses—without ketamine—would be enough to reverse anhedonia. They inserted a light-sensitive version of Rac1, a protein that clusters glutamate receptors, into the dopamine receptor type 1 neurons. Mice exposed to blue light showed restored motivation and sociability, while exposure to red light had no effect. The findings suggest that targeted synaptic enhancement alone can substitute for ketamine in relieving anhedonia.

To identify where the restored signals were coming from, the researchers injected a light-activated protein into several brain areas that send input to the nucleus accumbens. They found that chronic stress weakened glutamatergic connections from the medial prefrontal cortex and ventral hippocampus—regions involved in decision-making and memory. Ketamine restored both pathways but did not affect inputs from the amygdala, thalamus, or ventral tegmental area.

Further analysis revealed distinct mechanisms for each pathway. The prefrontal input gained stronger unitary synaptic responses, while the hippocampal input showed both stronger responses and increased release events. These changes indicate different modes of adaptation at the two inputs.

To confirm that both inputs were required for ketamine’s effects, the team used a two-virus strategy to express a designer inhibitory receptor specifically in either the prefrontal or hippocampal projection to the nucleus accumbens. Administering a drug that silenced the targeted neurons before ketamine blocked the behavioral rescue.

Interestingly, the type of failure depended on which pathway was silenced. Turning off the ventral hippocampal input delayed the animals’ first approach to a social partner and the first attempt to obtain a reward. In contrast, silencing the prefrontal input did not affect initiation, but reduced overall engagement. These results suggest that hippocampal input helps trigger reward-seeking, while prefrontal input helps sustain it.

“We’ve uncovered a brain mechanism through which ketamine restores reward-related behavior after chronic stress in mice, and we believe these mechanisms are likely conserved across species,” Pignatelli said. “That makes this discovery relevant for clinical applications.”

But, as with all research, there are limitations. “It is always important to highlight that our mechanistic studies are taking place by using murine animal models,” Pignatelli noted. “In general, the findings of a study in mice may not directly translate to humans or other species, but they offer valuable insights into biological processes within that model.”

Future studies could use brain imaging to examine whether similar changes occur in patients who recover from anhedonia after ketamine treatment. Identifying specific synapses that support antidepressant effects may eventually allow researchers to design drugs that improve motivation without the dissociative side effects associated with ketamine.

“I hope that results from this body of work will have a sustained impact on the field by propelling the rational design of more targeted treatments, thereby facilitating more effective and safer therapies aiming at alleviating anhedonia,” Pignatelli said.

The study, “Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens,” was authored by Federica Lucantonio, Jacob Roeglin, Shuwen Li, Jaden Lu, Aleesha Shi, Katherine Czerpaniak, Francesca R. Fiocchi, Leonardo Bontempi, Brenda C. Shields ,Carlos A. Zarate, Jr., Michael R. Tadross, and Marco Pignatelli.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

Psychedelic drug DOI activates specific brain neurons to ease anxiety
Depression

Choline imbalance in the brain linked to with cognitive symptoms in young depression patients

July 8, 2025

Researchers have identified metabolic differences in the brains of young adults with depression who also experience cognitive impairment. The study sheds light on how chemical imbalances in key brain regions may contribute to thinking and memory problems in depression.

Read moreDetails
Study links internalized racism to increased suicidal thoughts in Asian Americans
Depression

Breakfast habits are associated with depressive symptoms, study finds

July 6, 2025

Researchers found that young people in Hong Kong who regularly skip breakfast reported more depressive symptoms and lower attention control. The findings point to a subtle link between morning habits and emotional well-being.

Read moreDetails
Feminine advantage in harm perception obscures male victimization
Depression

People with depression face significantly greater social and health-related challenges

July 5, 2025

New findings reveal that depression is linked to both greater social hardship and increased frailty. People with depression were significantly more likely to report unmet basic needs and physical vulnerability, suggesting a complex relationship between social conditions and mental health.

Read moreDetails
Underweight individuals are at an increased risk of suicide, study finds
Depression

Subjective cognitive struggles strongly linked to social recovery in depression

July 3, 2025

In people with major depression, subjective feelings of cognitive dysfunction—rather than performance on cognitive tests—strongly predicted emotional symptoms and social functioning. The findings suggest that what patients think about their own thinking may be key to long-term recovery.

Read moreDetails
New study claims antidepressant withdrawal is less common than thought. But there’s a big problem
Depression

Longer antidepressant use linked to more severe, long-lasting withdrawal symptoms, study finds

July 1, 2025

A new study finds that the longer people take antidepressants, the more likely they are to face severe, long-lasting withdrawal symptoms—raising questions about current prescribing practices and the support available for those trying to stop the medication.

Read moreDetails
Researchers identify neural mechanism behind memory prioritization
Depression

Older adults who feel criticized by loved ones are more likely to develop depression

June 30, 2025

A new study shows that even mild criticism from loved ones can increase the risk of depression in older adults. The findings suggest that reducing negativity in close relationships may protect mental health in later life—especially for women.

Read moreDetails
Neuroscientists identify a reversible biological mechanism behind drug-induced cognitive deficits
Depression

New study links intermittent fasting to improved mood via brain’s dopamine system

June 27, 2025

A new study suggests that intermittent fasting may reduce symptoms of depression by activating dopamine D1 receptors in the brain’s prefrontal cortex. The findings point to a potential non-drug approach for mood disorders rooted in brain signaling.

Read moreDetails
Loss of empathy in frontotemporal dementia traced to weakened brain signals
Depression

New neuroscience research reveals brain antioxidant deficit in depression

June 22, 2025

A new meta-analysis suggests that people with major depressive disorder have lower levels of the brain antioxidant glutathione in the occipital cortex. The findings highlight a possible role for oxidative stress in depression and point to potential treatment targets.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Prenatal exposure to “forever chemicals” linked to autistic traits in children, study finds

Ketamine repairs reward circuitry to reverse stress-induced anhedonia

Neuroscientists decode how people juggle multiple items in working memory

Inside the bored brain: Unlocking the power of the default mode network

Choline imbalance in the brain linked to with cognitive symptoms in young depression patients

Scientists who relocate more often start Nobel research up to two years earlier

Sedentary time linked to faster brain aging in older adults, study finds

People with short-video addiction show altered brain responses during decision-making

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy